Biogen (BIIB)
(Delayed Data from NSDQ)
$195.81 USD
-3.55 (-1.78%)
Updated Sep 23, 2024 03:57 PM ET
After-Market: $196.90 +1.09 (0.56%) 7:02 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Income Statements
Fiscal Year end for Biogen Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9,836 | 10,173 | 10,982 | 13,445 | 14,378 |
Cost Of Goods | 2,533 | 2,278 | 2,110 | 1,805 | 1,955 |
Gross Profit | 7,302 | 7,895 | 8,872 | 11,639 | 12,423 |
Selling & Adminstrative & Depr. & Amort Expenses | 5,690 | 4,303 | 6,031 | 7,089 | 5,380 |
Income After Depreciation & Amortization | 1,612 | 3,592 | 2,841 | 4,550 | 7,043 |
Non-Operating Income | -316 | 0 | -1,096 | 497 | 83 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 1,297 | 3,592 | 1,745 | 5,048 | 7,126 |
Income Taxes | 135 | 633 | 53 | 992 | 1,158 |
Minority Interest | 0 | -85 | 172 | 60 | 0 |
Investment Gains/Losses | 0 | 3 | 35 | 5 | -79 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1,162 | 2,962 | 1,728 | 4,061 | 5,889 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 1,161 | 3,047 | 1,556 | 4,001 | 5,889 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 2,139 | 4,110 | 3,958 | 5,007 | 7,723 |
Depreciation & Amortization (Cash Flow) | 526 | 518 | 1,117 | 457 | 681 |
Income After Depreciation & Amortization | 1,612 | 3,592 | 2,841 | 4,550 | 7,043 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 145.60 | 146.00 | 149.60 | 161.30 | 187.40 |
Diluted EPS Before Non-Recurring Items | 14.72 | 17.67 | 19.22 | 33.70 | 33.57 |
Diluted Net EPS (GAAP) | 7.97 | 20.87 | 10.40 | 24.80 | 31.42 |
Fiscal Year end for Biogen Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 2,464.90 | 2,290.50 | 2,386.30 | 2,530.30 | 2,456.00 |
Cost Of Goods | 546.00 | 542.20 | 618.30 | 659.60 | 592.70 |
Gross Profit | 1,918.90 | 1,748.30 | 1,768.00 | 1,870.70 | 1,863.30 |
SG&A, R&D, and Dept/Amort Expenses | 1,135.00 | 1,189.80 | 1,409.10 | 1,711.90 | 1,276.40 |
Income After SG&A, R&D, and Dept/Amort Expenses | 783.90 | 558.50 | 358.90 | 158.80 | 586.90 |
Non-Operating Income | -85.20 | -93.70 | -67.30 | -300.00 | 121.20 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 698.70 | 464.80 | 291.60 | -141.20 | 708.10 |
Income Taxes | 115.10 | 71.40 | 42.70 | -72.90 | 114.80 |
Minority Interest | 0.00 | 0.00 | -0.80 | -0.20 | 1.70 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 583.60 | 393.40 | 248.90 | -68.30 | 593.30 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 583.60 | 393.40 | 249.70 | -68.10 | 591.60 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 145.90 | 145.90 | 145.70 | 144.80 | 145.50 |
Diluted EPS Before Non-Recurring Items | 5.28 | 3.67 | 2.95 | 4.36 | 4.02 |
Diluted Net EPS (GAAP) | 4.00 | 2.70 | 1.70 | -0.47 | 4.07 |